Earnings Call · Q1 FY2023·2023-05-09

Q1 23EPS -4.46%·Rev n/aQ4 22EPS +28.89%·Rev n/aQ3 22EPS +28.90%·Rev n/aQ2 22EPS +16.39%·Rev n/a⚠ consensus missing

NEKTAR THERAPEUTICS NKTR

Vivian Wu — Conference Call Host

Howard Robin — President and CEO

Jonathan Zalevsky — Chief of Research and Development

Sandra Gardiner — Acting Chief Financial Officer

−0.2%1d on move date+0.3% vs SPY3d−3.8%5d−0.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NKTR calls or request research access.

More NKTR calls Browse calls Request research access